SciSparc .(US:SPRC) Benzinga·2026-01-13 18:39Core Viewpoint - SciSparc Ltd. announced a definitive agreement to acquire a portfolio of medical endoscopy patents, aiming to expand its presence in the medical device sector and accelerate commercialization plans [1][2][3]. Group 1: Acquisition Details - The acquisition includes patents, trademarks, and related rights associated with endoscopic systems and medical cameras, specifically the MUSE endoscopic system designed for minimally invasive procedures [2]. - The company plans to issue ordinary shares to the seller at closing, which will represent approximately 19.99% of the company's outstanding stock [4]. - SciSparc may opt to issue pre-funded warrants instead of some shares at its discretion [5]. Group 2: Commercial Strategy - SciSparc intends to commercialize the acquired technologies immediately after the deal closes, aiming to replicate existing successful distribution models [4]. - The company plans to leverage licensing and regional partnerships to expand its market reach in North America, Europe, and Latin America [4]. Group 3: Closing Conditions and Market Outlook - The acquisition is subject to customary conditions, including regulatory approvals, with an expected closing date by March 8, 2026 [6]. - A market research report indicates growth in the global GERD device market, driven by demand for innovative endoscopy systems, which may help SciSparc extend its reach into new medical segments alongside its pharmaceutical initiatives [6]. Group 4: Stock Performance - Following the announcement, SciSparc shares were trading lower by 12.07% to $1.27 [7].